Trial · NCT01292655
Study to Evaluate the Safety and Tolerability of IV Doses of BMS-906024 in Subjects With Advanced or Metastatic Solid Tumors
NCT01292655, Phase 1, Completed, Bristol-Myers Squibb
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Study to Evaluate the Safety and Tolerability of IV Doses of BMS-906024 in Subjects With Advanced or Metastatic Solid Tumors. Trials, record NCT01292655. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01292655
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Study to Evaluate the Safety and Tolerability of IV Doses of BMS-906024 in Subjects With Advanced or Metastatic Solid Tumors
- NCT number
- NCT01292655
- Status
- Completed
- Phases
- Phase 1
- Enrollment
- 94 participants, actual
- Lead sponsor
- Bristol-Myers Squibb
- Conditions
- Cancer
- Interventions
- BMS-906024
- First posted
- 2011-02-09
- Last updated
- 2020-01-27
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of subjects with adverse events as a measure of safety and tolerability | Weekly assessments until study discontinuation due to disease progression or unacceptable adverse event as well as an assessment 30 day after treatment discontinuation with an average time on study expected to be <1 year | |
| Secondary | Tumor assessments using response evaluation criteria in solid tumors (RECIST) v1.1 | Tumor assessments at least every 8 weeks during treatment period | |
| Secondary | PD changes from baseline in the expression of Notch pathway-related genes in surrogate tissues (peripheral blood cells) and tumor biopsies | PD changes from baseline during the first 4-5 weeks of dosing | |
| Secondary | PK parameters for BMS-906024 and its metabolite BMS-911557, maximum observed concentration (Cmax) | PK at multiple time points during the first 8 weeks of dosing | |
| Secondary | PK parameters for BMS-906024 and its metabolite BMS-911557, minimum observed concentration (Cmin) | PK at multiple time points during the first 8 weeks of dosing | |
| Secondary | PK parameters for BMS-906024 and its metabolite BMS-911557, time to reach maximum observed concentration (Tmax) | PK at multiple time points during the first 8 weeks of dosing | |
| Secondary | PK parameters for BMS-906024 and its metabolite BMS-911557, terminal phase elimination half-life (T-Half) | PK at multiple time points during the first 8 weeks of dosing | |
| Secondary | PK parameters for BMS-906024 and its metabolite BMS-911557, accumulation index (AI) | PK at multiple time points during the first 8 weeks of dosing | |
| Secondary | PK parameters for BMS-906024 and its metabolite BMS-911557, area under the concentration-time curve (AUC) | PK at multiple time points during the first 8 weeks of dosing |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 34590610 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01292655
GET https://conductscience.org/api/trials/v1/NCT01292655/registered